FOUNDER SPOTLIGHT


ROCK MACKIE
Co-Founder and Chairman of the Board, TomoTherapy Incorporated /
Professor, University of Wisconsin-Madison

"The core technology of TomoTherapy was developed by National Cancer Institute funding and each year it is responsible for the treatment of tens of thousands of difficult to treat patients. It also generates many times its original funding level in salaries and taxes returned to both the United States and Wisconsin governments. Federal funding of technology is both economically and scientifically sound."

FAST FACTS


FOUNDER(S):
Thomas Rockwell Mackie, PhD
Paul Reckwerdt
INNOVATION(S):
Cancer Therapies/Tests
Medical Devices/Medical Diagnostics
EMPLOYEES:
600
HEADQUARTERS:
Madison, WI
FOUNDED:
1997
REVENUE:
$232.8 million FY 2008
TSC MEMBER INSTITUTION(S):
University of Wisconsin-Madison
FUNDING AGENCY(S):
National Institutes of Health
STATUS:
Public

TOMOTHERAPY INCORPORATED

ABOUT THE COMPANY:

TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. More than 300 TomoTherapy systems are installed worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.

UNIVERSITY-BASED RESEARCH CONNECTION:

University of Wisconsin-Madison professors Thomas Mackie and Paul Reckwerdt wanted to solve a major problem in cancer treatment therapy — the serious damage to normal tissues and organs created by standard radiation therapy. They were intrigued with the idea of building a machine that could deliver radiation in a fashion that more accurately targeted cancerous tumors, while minimizing radiation exposure to surrounding tissue. The result is the Hi·Art® system, unique among linear accelerators in its CT platform-based design. With integrated CT imaging and helical delivery capabilities, it is the only device developed from the ground up for image-guided, intensity modulated radiation therapy.
 
Today, physicians in more than 20 countries use this remarkable technology to customize a treatment plan that delivers a precisely configured field of radiation to the tumor that is essentially the same shape and volume as the tumor itself.

ROLE OF FEDERAL RESEARCH FUNDING:

The initial research and development was undertaken at the University of Wisconsin-Madison with a $250,000 grant from the National Cancer Institute, part of the National Institutes of Health.

TOMOTHERAPY INCORPORATED
1240 DEMING WAY
MADISON, WI 53717-1954
WWW.TOMOTHERAPY.COM

Read The Full Report Here